Respiratory diseases—which develop particularly in hospitals, such as those resulting from Pa infections—remain a scourge for which there is currently no effective vaccine. Often resistant to antibiotics, Pa infection is a leading cause of hospital-acquired illness and of infections that are sometimes fatal in people with cystic fibrosis.
Glycovax Pharma has optimized manufacturing of the GVX-PA-01 vaccine, based on an antigen identified by the National Research Council of Canada (NRC), by incorporating the SLA adjuvant. Glycovax is advancing the vaccine’s preclinical development in collaboration with the NRC and the Université de Montréal’s Faculty of Veterinary Medicine, thanks to a $467,661 grant from CQDM on behalf of the Government of Quebec.